<DOC>
	<DOCNO>NCT00226746</DOCNO>
	<brief_summary>The purpose study find effect , good bad , chemotherapy drug gemcitabine ( Gemzar ) paclitaxel ( Taxol ) combination twice daily radiation treatment locally advance pancreatic cancer .</brief_summary>
	<brief_title>Efficacy Study Gemcitabine , Paclitaxel , Irradiation Treatment Pancreatic Cancer</brief_title>
	<detailed_description>Based previous experience use weekly paclitaxel dose 60 mg/m2 hyperfractionated radiation therapy 63.8 Gy , conduct study incorporate use Gemcitabine dose level 75 mg/m2/week addition prior protocol .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Pancreatic Ductal</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . Pathologically confirm adenocarcinoma pancreas . 2 . Patients must locally advanced/unresectable disease base institutional standardized criterion unresectability . 3 . Patients residual disease resection ( R1 –2 , micro macroscopic residual ) eligible . 4 . Patients biliary gastroduodenal obstruction must drainage prior start chemoradiation . 5 . All malignant disease must encompassable within single irradiation field ( 12 x 12 cm maximum ) . 6 . All patient must radiographically assessable disease . 7 . Electrocardiogram ( EKG ) , chest xray , abdominal compute tomography ( CT ) /magnetic resonance imaging ( MRI ) scan must obtain within four week study entry . 8 . Zubrod performance status 01 . 9 . Required entry laboratory parameter : granulocyte &gt; /= 1,800/µl , platelet count &gt; /= 100,000/µl , bilirubin &lt; 2.0 mg/dL , ALT &lt; 3 x upper limit normal , creatinine &lt; 3.0 mg/dL . 10 . Signed studyspecific consent form prior study entry . 1 . Patients evidence metastatic disease major viscera and/or peritoneal seed ascites . 2 . Previous irradiation plan field ; previous chemotherapy pancreatic cancer ( Gemzar® Taxol® ) . 3 . Malignancy ( within past two year ) except nonmelanomatous skin cancer carcinoma situ cervix , uterus , bladder . 4 . Patients significant infection coexistent medical condition would preclude protocol therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>Pancreatic Cancer</keyword>
	<keyword>Hyperfractionated Radiation Therapy</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Carcinoma , Pancreatic Ductal</keyword>
</DOC>